文献速递膀胱癌与上尿路尿路上皮癌

复发低级别中危非肌层浸润性膀胱癌患者对手术及非手术一线治疗影响其日常事务与责任的感知:ENVISION 3期试验结果

Perceived Impact on Patient Routines/Responsibilities for Surgery and a Nonsurgical Primary Treatment Option in Recurrent Low-Grade Intermediate-Risk Nonmuscle-Invasive Bladder Cancer: Findings From the ENVISION Phase 3 Trial.
PubMed 文献 · J Urol · 2025-03-06

ENVISION为3期单臂试验,UGN-102(含丝裂霉素)每周膀胱灌注共6次;对美国41例患者入组时及3个月时访谈,29例完成两次访谈,归纳出三个主题:患者认为经尿道膀胱肿瘤电切术(TURBT)对日常事务与责任干扰更大,泌尿症状感知相似但TURBT出血、导管问题及恢复性生活时间更长,患者因UGN-102创伤更小、疼痛更轻、更省时而愿意推荐给他人。

要点

  • 患者感知TURBT对日常事务与责任的干扰大于UGN-102膀胱灌注。
  • 泌尿症状感知相似,但TURBT出血、导管问题及恢复性生活时间更长。
  • 患者因UGN-102创伤更小、疼痛更轻、更省时而愿意向他人推荐。

核心结论

  • 患者认为UGN-102是低级别中危非肌层浸润性膀胱癌传统手术切除的一种有利的一线治疗替代选择。
  • 通过聚焦患者感知这一未被充分探索的领域,本研究为泌尿外科医生开展共享决策对话提供了关键信息。

研究设计与样本

  • ENVISION为3期单臂试验,UGN-102以每周膀胱灌注给药共6次。
  • 对美国患者于入组时(灌注前)及3个月(主要试验终点)进行访谈,41例来自31个中心符合条件,其中29例完成两次访谈。
  • 参与患者中男性占62%、白人占83%、65岁及以上占69%。
  • 转录文本由3名编码者采用内容分析金标准进行编码以归纳访谈主题。

主要发现

  • 归纳出三个主题:患者感知TURBT对日常事务与责任的干扰更大。
  • 患者感知泌尿症状相似,但TURBT出血、导管问题及恢复性生活时间更长。
  • UGN-102不常见的报告为灌注期间膀胱内瘙痒及难以将凝胶保留在膀胱内。
  • 患者愿意向其他患者推荐UGN-102,因为感知其较TURBT创伤更小、疼痛更轻、更省时。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: Adults with low-grade intermediate-risk nonmuscle-invasive bladder cancer commonly ask urologists how their routine/responsibilities will be affected by treatments, including the standard of care, transurethral resection of bladder tumor (TURBT). We asked patients in the ENVISION trial to compare TURBT with a nonsurgical primary treatment (UGN-102 containing mitomycin) for acceptability and impact on their routine/responsibilities. MATERIALS AND METHODS: ENVISION is a phase 3, single-arm trial where UGN-102 was administered as 6 weekly intravesical instillations. Interviews with US patients were conducted at enrollment (before instillations) and 3 months (primary trial end point). Transcripts were coded by 3 coders using the gold standard of content analysis to derive interview themes. RESULTS: Forty-one US patients from 31 sites were eligible, and 29 of 41 completed both interviews. Most of the participating patients were male (62%), White (83%), and of age 65+ years (69%). Three themes were derived: (1) Patients perceived that TURBT interfered more with their routine/responsibilities. (2) Urinary symptoms were perceived to be similar, but bleeding, catheter issues, and time to resuming sexual activity lasted longer with TURBT. For UGN-102, uncommon reports were internal itching and difficulty keeping gel in the bladder during instillations. (3) Patients would recommend UGN-102 to other patients because it was perceived to be less invasive, painful, and time-consuming than TURBT. CONCLUSIONS: Patients perceived UGN-102 to be a favorable primary treatment alternative to traditional surgical resections for low-grade intermediate-risk nonmuscle-invasive bladder cancer. By focusing on the underexplored area of patient perceptions, this study provides key information urologists will need to conduct shared decision-making conversations. TRIAL REGISTRATION: ClinicalTrials.gov Identifier: NCT05243550.

来源:J Urol,查看原文。版权归原作者所有。

引用

  1. Stover AM, Mueller D, Carda-Auten J, et al. Perceived Impact on Patient Routines/Responsibilities for Surgery and a Nonsurgical Primary Treatment Option in Recurrent Low-Grade Intermediate-Risk Nonmuscle-Invasive Bladder Cancer: Findings From the ENVISION Phase 3 Trial. J Urol. 2025. PMID: 40048558. doi:10.1097/JU.0000000000004511

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。